Amy H. Huang, MD
@amyhuangmd
@UConn IM PGY-3 | 2025 @ASCO Conquer Cancer Merit Award Recipient | Aspiring Hematologist/Oncologist #CRC#lungcancer #myeloma#bigdata#healthequity#AI
➡️ #ASCOGI25 Our merit award-winning meta-analysis on EGFRi rechallenge for metastatic colorectal cancer: 🔴 EGFRi rechallenge: significantly ⬆️ PFS than EGFRi-free systemic therapy, esp. for RAS/RAF-wild type mCRC Mentor @ronanhsieh @fredhutch @UConn @DanaFarber @cityofhope
[HemOnc fellowship applicant AAMC ID 13775508] I am a resident from UConn (University of Connecticut) pursuing a career in academic Hematology/Oncology. Two years ago, I immigrated from Taiwan to Houston after obtaining a green card based on my research contributions. I have…
![amyhuangmd's tweet image. [HemOnc fellowship applicant AAMC ID 13775508]
I am a resident from UConn (University of Connecticut) pursuing a career in academic Hematology/Oncology. Two years ago, I immigrated from Taiwan to Houston after obtaining a green card based on my research contributions. I have…](https://pbs.twimg.com/media/GwVgA3bW8AAa1t3.jpg)
Just out: FDA grants accelerated approval to linvoseltamab for treatment of relapsed/refractory myeloma. It is the 3rd BCMA bispecific antibody approved for myeloma. I welcome the choice that patients and physicians have. ajmc.com/view/fda-appro…
Just out! Latest NCCN guidelines has added daratumumab as Category 1 recommendation for high risk smoldering myeloma. In AQUILA trial, daratumumab: -Delayed progression to active myeloma -Delayed time to needing full myeloma therapy -Better overall survival
Key Myeloma therapy update for 2025 1) Newly diagnosed: Start treatment with quads, if possible. (Dara-VRd or Isa-VRd). 2) Auto Transplant: can be deferred for standard risk patients, especially if good response to induction. But collect and store stem cells for future use.…
💫@ASCO #ASCO25 #IMGoncCOP meeting was so genuine, collaborative, and uplifting! 💎With >200 attendees and 20 presenters, we came together to share real experiences, emotional and logistical burdens of moving from abroad, guided the next generation on tackling challenges, and…
#ASCO25 IMG CoP was one of a kind! @NazliDizman @ZiadBakouny & doctors from all over the 🌏 unpacked their paths and personal experience —J-1 → O-1 → EB1 🛂, years of re-training 🩺, learning new cultures, languages, etc… Mentorship tracks and opportunities, workshops, and the…
Just out. Updated myeloma mSMART guidelines on prevention and management of bispecific antibody associated Toxicities. @YiLinMDPhD @MayoMyeloma #ASCO25 Comprehensive and covers CRS, neurotoxicity, infection prevention and more. Link: msmart.org/mm-treatment-g…
Thank you, Dr. Rami Manochakian, for sharing your insights at the Hematology/Oncology fellowship application roundtable hosted by the @ASCOTECAG! The session was incredibly helpful in clarifying many of our questions! #ASCO25 @ASCO #MayoClinicFL @MayoCancerCare…
Finally met my mentor, Dr. Jyoti Malhotra from City of Hope, in person! I am so thankful for her guidance and support as I shape my career!❤️ @JyotiMalhotraMD @cityofhopeoc @uconnhealth #ASCO25
Starting now! ⏰ Are you interested in #pallonc combined programs supported through @ASCO? DM me for a link and join us. Pleased to join my @PallOncCoP co-champ @MazieTsangMD in sharing our experiences in #supponc for the next generation of bright physicians @PallOncCoP…